SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
From the Blogosphere
Unusual 11 Mid-Day Movers 10/17: CIT, ICUI, MPEL, UAUA Higher; LBY, POZN, ING, PPC Lower
|
CIT Group (NYSE: CIT) 39.9% HIGHER; after reporting a Q3 loss of $1.13, shares of CIT fell about 36% yesterday. The stock appears to be correcting after yesterday's large slide.
Libbey Inc. (NYSE: LBY) 37% LOWER; reports preliminary Q3 sales of $211.5 million, versus the consensus of $220.14 million. Sees FY08 sales in the range of $833-$843 million, versus the consensus of $876.25 million.
POZEN Inc. (NASDAQ: POZN) 28.7% LOWER; today announced that the U.S. FDA has informed the Company that, as part of the FDA's on-going discussions with the Company and their review of both the Special
|
POZEN, Inc. (POZN) Chairman and CEO Presents Company Update at Conference
|
|
|
<>At the Jefferies 2nd Annual Healthcare Conference in New York, Dr. John R. Plachetka, Chairman and CEO of POZEN presented in regards to the company’s main product Treximet???. POZEN has obtained commercialization and development alliances with GlaxoSmithKline for Treximet??? (sumatriptan and naproxen sodium), which was recently approved by the FDA for the acute treatment of migraine attacks in adults. Additionally, the company has an agreement with AstraZeneca for proprietary fixed dose combinations of naproxen with the proton pump inhibitor esomerprazole magnesium, designed specifically <><>< /><><>...
|
POZEN, Inc. (POZN) Chairman and CEO Presents Company Update at Conference
|
|
|
<>At the Jefferies 2nd Annual Healthcare Conference in New York, Dr. John R. Plachetka, Chairman and CEO of POZEN presented in regards to the company’s main product Treximet™. POZEN has obtained commercialization and development alliances with GlaxoSmithKline for Treximet™ (sumatriptan and naproxen sodium), which was recently approved by the FDA for the acute treatment of migraine attacks in adults. Additionally, the company has an agreement with AstraZeneca for proprietary fixed dose combinations of naproxen with the proton pump inhibitor esomerprazole magnesium, designed specifically for <><>< /><><><><>< /><>< /><>< />< />...
|
The Black Crowes - She Talks To Angels
POZN
Buy-Rated Pozen Worth the Risks
POZN
|
We expect the second quarter 2008 will be positive with respect to EPS and cash-flow based on the $20 million Glaxo milestone on the approval of Treximet.
|
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
| StreetInsider.com on POZN |
Visit streetinsider.com
Be the first to start a discussion and earn 2 points.
More Resources
|
About Pozen Inc.
- Answers.com
